Article Text

Download PDFPDF
Ceftriaxone-resistant Neisseria gonorrhoeae, Puerto Rico
  1. Ramón Scharbaai-Vázquez1,2,
  2. Ana L González-Caraballo2,
  3. Luis J Torres-Bauzá2
  1. 1San Juan Bautista School of Medicine, Caguas, Puerto Rico
  2. 2Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico
  1. Correspondence to Dr Ramón Scharbaai-Vázquez; San Juan Bautista School of Medicine, P.O. Box 4968, Caguas 00726-4968, Puerto Rico; RScharbaai{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Emergence and spread of multidrug-resistant Neisseria gonorrhoeae is a global threat. The aetiological agent of gonorrhoea has developed resistance to first-line treatments, such as sulfanilamides, penicillins, tetracyclines, macrolides, and fluoroquinolones1 The extended-spectrum cephalosporins are now the only antibiotics recommended for treatment of gonorrhoea in the USA and many countries.2 ,3 Unfortunately, susceptibility to these antimicrobials has also decreased.4–7 This trend has made the Centers for Disease Control (CDC) to recently classify N. gonorrhoeae as an urgent public health threat.8

We report here the first N. gonorrhoeae isolate …

View Full Text


  • Contributors ALG-C collected and analysed data. RS-V and LJT-B conceived the study. RS-V wrote the first and last drafts. All authors had full access to all the data in the study, and take responsibility for the integrity of the data and the accuracy of the data analysis.

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the participating institutions.

  • Provenance and peer review Not commissioned; internally peer reviewed.